JP2021519076A5 - - Google Patents
Info
- Publication number
- JP2021519076A5 JP2021519076A5 JP2020551572A JP2020551572A JP2021519076A5 JP 2021519076 A5 JP2021519076 A5 JP 2021519076A5 JP 2020551572 A JP2020551572 A JP 2020551572A JP 2020551572 A JP2020551572 A JP 2020551572A JP 2021519076 A5 JP2021519076 A5 JP 2021519076A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- agent
- psma
- antibody
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103109A JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650277P | 2018-03-29 | 2018-03-29 | |
| US62/650,277 | 2018-03-29 | ||
| PCT/US2019/025057 WO2019191728A1 (en) | 2018-03-29 | 2019-03-29 | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103109A Division JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519076A JP2021519076A (ja) | 2021-08-10 |
| JP2021519076A5 true JP2021519076A5 (https=) | 2022-04-06 |
| JPWO2019191728A5 JPWO2019191728A5 (https=) | 2022-04-06 |
| JP7512202B2 JP7512202B2 (ja) | 2024-07-08 |
Family
ID=66103056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551572A Active JP7512202B2 (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
| JP2024103109A Pending JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103109A Pending JP2024123231A (ja) | 2018-03-29 | 2024-06-26 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12059473B2 (https=) |
| EP (2) | EP4461318A3 (https=) |
| JP (2) | JP7512202B2 (https=) |
| KR (2) | KR20250141858A (https=) |
| CN (2) | CN117924503A (https=) |
| AU (2) | AU2019245444B2 (https=) |
| BR (1) | BR112020019611A2 (https=) |
| CA (2) | CA3282900A1 (https=) |
| DK (1) | DK3773910T3 (https=) |
| ES (1) | ES2988767T3 (https=) |
| FI (1) | FI3773910T3 (https=) |
| HR (1) | HRP20241082T1 (https=) |
| HU (1) | HUE068337T2 (https=) |
| IL (2) | IL277357B2 (https=) |
| LT (1) | LT3773910T (https=) |
| MX (2) | MX2020010104A (https=) |
| PL (1) | PL3773910T3 (https=) |
| PT (1) | PT3773910T (https=) |
| RS (1) | RS66103B1 (https=) |
| SG (1) | SG11202009670RA (https=) |
| SI (1) | SI3773910T1 (https=) |
| SM (1) | SMT202400364T1 (https=) |
| WO (1) | WO2019191728A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021086917A1 (en) * | 2019-10-29 | 2021-05-06 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| US20230071763A1 (en) * | 2020-01-06 | 2023-03-09 | Cytomx Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| EP4221763A4 (en) * | 2020-10-01 | 2025-11-12 | Univ Cornell | METHODS AND COMPOSITIONS FOR INCREASING THE ABSORPTION, INTERNALIZATION AND/OR RETENTION OF SMALL MOLECULE LIGANDS |
| US20230374150A1 (en) * | 2020-10-12 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| US20230390411A1 (en) * | 2021-01-28 | 2023-12-07 | Nanjing Chempion Biotechnology Co., Ltd. | Conjugate and use thereof |
| JP2025535713A (ja) | 2022-10-07 | 2025-10-28 | アンブレツクス・インコーポレイテツド | 薬物リンカー及びその抗体コンジュゲート |
| WO2024178310A1 (en) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Trop2-directed antibody-drug conjugates and uses thereof |
| WO2024182569A2 (en) * | 2023-02-28 | 2024-09-06 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| AU2023448948A1 (en) * | 2023-05-24 | 2025-10-09 | Hangzhou Dac Biotech Co., Ltd | Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate |
| TW202521545A (zh) * | 2023-08-04 | 2025-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｐｓｍａ抗體－藥物偶聯物及其醫藥用途 |
| IL326709A (en) * | 2023-08-22 | 2026-04-01 | Ambrx Inc | Anti-PSMA ADC conjugate compositions and methods of using them |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| CN118754934B (zh) * | 2024-06-05 | 2025-02-07 | 浙江新码生物医药有限公司 | 一种用于制备药物偶联物的毒素衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
| AU2015203742B2 (en) | 2007-06-26 | 2016-12-01 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| PT2318029T (pt) | 2008-07-23 | 2018-01-10 | Ambrx Inc | Polipéptidos de g-csf bovino modificados e suas utilizações |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US10800856B2 (en) * | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| JP2015521602A (ja) * | 2012-06-14 | 2015-07-30 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 核受容体リガンドポリペプチドに対して複合化されている抗ｐｓｍａ抗体 |
| JP6584012B2 (ja) * | 2013-10-06 | 2019-10-02 | アメリカ合衆国 | 改変シュードモナス外毒素ａ |
| WO2017212250A1 (en) * | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| EP3630977B1 (en) | 2017-06-02 | 2024-02-21 | Ambrx, Inc. | Methods and compositions for promoting non-natural amino acid-containing protein production |
-
2019
- 2019-03-29 US US17/042,838 patent/US12059473B2/en active Active
- 2019-03-29 IL IL277357A patent/IL277357B2/en unknown
- 2019-03-29 MX MX2020010104A patent/MX2020010104A/es unknown
- 2019-03-29 BR BR112020019611-8A patent/BR112020019611A2/pt unknown
- 2019-03-29 PT PT197171739T patent/PT3773910T/pt unknown
- 2019-03-29 SI SI201930799T patent/SI3773910T1/sl unknown
- 2019-03-29 HR HRP20241082TT patent/HRP20241082T1/hr unknown
- 2019-03-29 PL PL19717173.9T patent/PL3773910T3/pl unknown
- 2019-03-29 FI FIEP19717173.9T patent/FI3773910T3/fi active
- 2019-03-29 WO PCT/US2019/025057 patent/WO2019191728A1/en not_active Ceased
- 2019-03-29 RS RS20241125A patent/RS66103B1/sr unknown
- 2019-03-29 SM SM20240364T patent/SMT202400364T1/it unknown
- 2019-03-29 CN CN202410093812.9A patent/CN117924503A/zh active Pending
- 2019-03-29 IL IL320375A patent/IL320375A/en unknown
- 2019-03-29 CA CA3282900A patent/CA3282900A1/en active Pending
- 2019-03-29 EP EP24190121.4A patent/EP4461318A3/en active Pending
- 2019-03-29 ES ES19717173T patent/ES2988767T3/es active Active
- 2019-03-29 CN CN201980025915.9A patent/CN111989138B/zh active Active
- 2019-03-29 JP JP2020551572A patent/JP7512202B2/ja active Active
- 2019-03-29 KR KR1020257031656A patent/KR20250141858A/ko active Pending
- 2019-03-29 AU AU2019245444A patent/AU2019245444B2/en active Active
- 2019-03-29 DK DK19717173.9T patent/DK3773910T3/da active
- 2019-03-29 CA CA3094985A patent/CA3094985C/en active Active
- 2019-03-29 LT LTEPPCT/US2019/025057T patent/LT3773910T/lt unknown
- 2019-03-29 HU HUE19717173A patent/HUE068337T2/hu unknown
- 2019-03-29 EP EP19717173.9A patent/EP3773910B1/en active Active
- 2019-03-29 SG SG11202009670RA patent/SG11202009670RA/en unknown
- 2019-03-29 KR KR1020207030091A patent/KR102864931B1/ko active Active
-
2020
- 2020-09-25 MX MX2024007724A patent/MX2024007724A/es unknown
-
2024
- 2024-06-26 JP JP2024103109A patent/JP2024123231A/ja active Pending
- 2024-07-01 US US18/761,130 patent/US20240350835A1/en active Pending
-
2025
- 2025-06-26 AU AU2025204809A patent/AU2025204809A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519076A5 (https=) | ||
| FI3773910T3 (fi) | Humanisoituja eturauhasspesifisen membraaniantigeeni (psma) -vasta-aineen ja lääkkeen konjugaatteja | |
| JPWO2019191728A5 (https=) | ||
| JP2015534578A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2015534577A5 (https=) | ||
| JP2008546792A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| JP2019031565A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2013518912A5 (https=) | ||
| JP2017110002A5 (https=) | ||
| JP2003528924A5 (https=) | ||
| JP2021505540A5 (https=) | ||
| JP2017507931A5 (https=) | ||
| WO2005044307A3 (en) | Methods of therapy for b cell-related cancers | |
| JP2015531750A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| JP2019500327A5 (https=) | ||
| JP2003519096A5 (https=) | ||
| JP2006506441A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2010520280A5 (https=) | ||
| JP2022513684A5 (https=) | ||
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 |